Calidi Biotherapeutics
CLDI
33 hedge funds and large institutions have $1.27M invested in Calidi Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 5 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
249% more capital invested
Capital invested by funds: $363K → $1.27M (+$903K)
65% more funds holding
Funds holding: 20 → 33 (+13)
0.16% more ownership
Funds ownership: 0.33% → 0.49% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$213K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$188K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$160K |
| 4 |
DWM
Drive Wealth Management
Lehi,
Utah
|
+$141K |
| 5 |
VF
Virtu Financial
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCC
Cable Car Capital
San Francisco,
California
|
-$94.5K |
| 2 |
6CM
683 Capital Management
New York
|
-$4.32K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.18K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$825 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$161 |
CLDI Hedge Fund Activity: Q4 2024 in Review
33 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q4 2024, worth a combined $1.27M — up 249% from $363K a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CLDI positions and 5 closed out — a net gain of 13 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $213K. The largest seller was Cable Car Capital, exiting entirely with an estimated $94.5K sold.
- 33 institutional investors held Calidi Biotherapeutics (CLDI) as of Q4 2024, up from 20 in Q3 2024.
- Funds reported $1.27M of Calidi Biotherapeutics stock for Q4 2024, up 249% quarter-over-quarter.
- 18 funds opened new Calidi Biotherapeutics positions in Q4 2024 and 5 closed out, a net change of +13 holders.
- The largest Calidi Biotherapeutics buyer in Q4 2024 was Millennium Management, an estimated $213K added.
- The largest Calidi Biotherapeutics seller in Q4 2024 was Cable Car Capital, an estimated $94.5K sold.
Based on aggregated 13F filings for Q4 2024.